Research chemicalResearch chemicalBenzodiazepine analogueDepressant

Nitrazolam

Also known as Nitrazolam

Written by enwyReviewed 4 Aug 20261 sources0 comments

Nitrazolam is a triazolo designer benzodiazepine structurally related to alprazolam, distinguished by a nitro group. It has no medical use and appears only as a research chemical. Like other triazolobenzodiazepines it is a potent GABA-A positive allosteric modulator producing strong sedation and anxiolysis, often active at sub-milligram to low-milligram doses.

01 Overview

Nitrazolam emerged on the novel psychoactive substance market as one of a series of alprazolam-like triazolobenzodiazepines. It is reported to be highly potent, so small differences in dose can produce large differences in effect, and blotter or pellet products carry a high risk of unintentional overdose.

Human data are limited to forensic and self-report sources. Purity and content of grey-market material are unreliable, and its high potency compounds the standard benzodiazepine risks of dependence, blackout amnesia and dangerous combination with other depressants.

02 Mechanism

Positive allosteric modulator at the GABA-A benzodiazepine site; triazole ring confers high potency similar to alprazolam.

03 Dosing

Tier	Dose	Route	Notes
Threshold	0.1–0.3 mg	Oral	Anecdotal.
Common	0.5–1.5 mg	Oral	Anecdotal; high potency means precise measurement matters.

04 Effects

Effect	Magnitude	Evidence
AnxiolysisMarked anxiety reduction.		Anecdotal
SedationStrong sedation and drowsiness.		Anecdotal
DisinhibitionReduced behavioural inhibition, sometimes with impulsive behaviour.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Dependence and withdrawalRapid tolerance, dependence and a severe withdrawal syndrome with seizure risk.	Severe	Common with regular use	Anecdotal
Respiratory depressionSuppressed respiration, greatly increased with opioids or alcohol.	Life-threatening	Uncommon alone, higher with CNS depressants	Anecdotal
Anterograde amnesia and blackoutMemory loss and blackout, with risk of compulsive redosing during amnesia.	Moderate	Common at higher doses	Anecdotal

06 Legal status

United States

Not scheduled by name

Possible analogue treatment under federal law. · as of Jan 2026

United Kingdom

Class C

Covered by generic benzodiazepine control. · as of Jan 2026

07 References

Designer benzodiazepines: a review of published dataDrug Testing and Analysis

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.